Otti Gref - Biovica International RD Director

BIOVIC-B

SEK 1.83 0.07 3.68%

Insider

Otti Gref is RD Director of Biovica International AB

Age	55
Phone	46 1 84 44 48 30
Web	https://www.biovica.com

Biovica International Management Efficiency

The company has return on total asset (ROA) of (0.3558) % which means that it has lost $0.3558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6505) %, meaning that it generated substantial loss on money invested by shareholders. Biovica International's management efficiency ratios could be used to measure how well Biovica International manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Biovica International to Peers

Predict price of Biovica International

Biovica International AB has accumulated 8.78 M in total debt. Biovica International has a current ratio of 2.51, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Biovica International until it has trouble settling it off, either with new capital or with free cash flow. So, Biovica International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biovica International sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biovica to invest in growth at high rates of return. When we think about Biovica International's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Peter Madsen	Cantargia AB	N/A
	Marcuss	Cantargia AB	N/A
	Anne Lanner	Hansa Biopharma AB	54
	Thoas MD	Cantargia AB	61
	Pr Gellerfors	BioArctic AB	76
	Dominique Tersago	Cantargia AB	61
	Klaus Sindahl	Hansa Biopharma AB	N/A
	Kjell Sjstrm	Cantargia AB	N/A
	Pr Lannfelt	BioArctic AB	74
	Erik Domines	Xbrane Biopharma AB	59
	Christer Mller	BioArctic AB	64
	Samuel Wagner	Xbrane Biopharma AB	N/A
	Sren MSc	Hansa Biopharma AB	58
	Martin mark	Xbrane Biopharma AB	43
	Gunilla Osswald	BioArctic AB	62
	Oskar Bosson	BioArctic AB	47
	Nina Ivers	Xbrane Biopharma AB	53
	Susanne Lagerlund	Cantargia AB	N/A
	Anette Lindqvist	Xbrane Biopharma AB	57
	Frida Lekander	BioArctic AB	N/A
	Emanuel Bjrne	Hansa Biopharma AB	50

Biovica International AB , a biotech company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome. Biovica International AB was founded in 2009 and is based in Uppsala, Sweden. Biovica International operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 17 people. Biovica International AB (BIOVIC-B) is traded on Stockholm Exchange in Sweden and employs 27 people.

Management Performance

	Return On Equity	-0.65
	Return On Asset	-0.36

Biovica International Leadership Team

Elected by the shareholders, the Biovica International's board of directors comprises two types of representatives: Biovica International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biovica. The board's role is to monitor Biovica International's management team and ensure that shareholders' interests are well served. Biovica International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biovica International's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Cecilia Driving, CFO CEO
	Mattias Bergqvist, VP Devel
	Henrik DVM, Sr Devel
	Anders Rylander, CEO Director
	Tomas Andersson, VP Operations
	Otti Gref, RD Director
	Joakim Arwidson, VP QA
	Warren Cresswell, Pres Americas

Biovica Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biovica International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.65
	Return On Asset	-0.36
	Operating Margin	(14.77) %
	Current Valuation	175.91 M
	Shares Outstanding	39.47 M
	Shares Owned By Institutions	3.73 %
	Price To Book	2.26 X
	Price To Sales	48.31 X
	Revenue	2.04 M
	Gross Profit	4.73 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Other Information on Investing in Biovica Stock

Biovica International financial ratios help investors to determine whether Biovica Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biovica with respect to the benefits of owning Biovica International security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC